These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 227427)
1. The effect of beta-pyridylcarbinol on lipoprotein lipids in primary type IIa hyperlipoproteinemia. Schwandt P; Weisweiler P; Neureuther G Atherosclerosis; 1979 Sep; 34(1):35-9. PubMed ID: 227427 [TBL] [Abstract][Full Text] [Related]
2. [Effect of beta-pyridylcarbinol on lipids and lipoprotein in primary type IIa hyperlipoproteinemia]. Hutt V; Wechsler JG; Klör HU; Ditschuneit H Arzneimittelforschung; 1983; 33(12):1682-4. PubMed ID: 6686774 [TBL] [Abstract][Full Text] [Related]
3. The effect of cholestyramine on lipoprotein lipids in patients with primary type IIA hyperlipoproteinemia. Weisweiler P; Neureuther G; Schwandt P Atherosclerosis; 1979 Jul; 33(3):295-300. PubMed ID: 226105 [TBL] [Abstract][Full Text] [Related]
4. The effect of D-thyroxine on lipoprotein lipids and apolipoproteins in primary type IIa hyperlipoproteinemia. Schwandt P; Weisweiler P Atherosclerosis; 1980 Mar; 35(3):301-6. PubMed ID: 6987993 [TBL] [Abstract][Full Text] [Related]
5. Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs. Wechsler JG; Hutt V; Klör HU; Ditschuneit H Artery; 1980; 8(6):519-29. PubMed ID: 7259531 [TBL] [Abstract][Full Text] [Related]
6. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia. Gavish D; Oschry Y; Fainaru M; Eisenberg S Eur J Clin Invest; 1986 Feb; 16(1):61-8. PubMed ID: 3084275 [TBL] [Abstract][Full Text] [Related]
7. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia. Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797 [TBL] [Abstract][Full Text] [Related]
8. Lipid composition of serum lipoproteins in patients with primary type IIb and type IV hyperlipoproteinemia. Weisweiler P; Schwandt P Atherosclerosis; 1978 Sep; 31(1):53-8. PubMed ID: 213086 [TBL] [Abstract][Full Text] [Related]
9. Serum lipoprotein composition in different types of hyperlipoproteinemia. Carlson LA Adv Exp Med Biol; 1975; 63():185-99. PubMed ID: 173148 [TBL] [Abstract][Full Text] [Related]
10. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia. Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951 [TBL] [Abstract][Full Text] [Related]
11. [Composition of VLDL, LDL and HDL lipoprotein fractions in type IIa, IIb, III, IV, and V hyperlipemia patients in comparison with healthy individuals]. Hutt V; Klör HU; Wechsler JG; Ditschuneit H J Clin Chem Clin Biochem; 1984 Feb; 22(2):141-6. PubMed ID: 6716054 [TBL] [Abstract][Full Text] [Related]
12. The hypolipidemic action of probucol. Drug transport and lipoprotein composition in type IIa hyperlipoproteinemia. Dachet C; Jacotot B; Buxtorf JC Atherosclerosis; 1985 Dec; 58(1-3):261-8. PubMed ID: 4091882 [TBL] [Abstract][Full Text] [Related]
13. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V]. Hutt V; Wechsler JG; Klör HU; Ditschuneit H Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558 [TBL] [Abstract][Full Text] [Related]
14. [Comparison between combination therapy with clofibrate and beta-pyridylcarbinol and clofibrate monotherapy (author's transl]. Mordasini R; Müller A; Klose G; Middelhoff G; Augustin J; Haase W; Greten H MMW Munch Med Wochenschr; 1978 Apr; 120(15):525-8. PubMed ID: 206826 [TBL] [Abstract][Full Text] [Related]
15. Clinical study of niceritrol on serum lipids in the treatment of hyperlipidemia. Kibata M; Ishida M; Asano K; Uehara H; Saito K; Fuchimoto T; Ugaki K; Murakami H; Matoba K; Kotakemori Y; Shirai K; Yoshioka H; Nanba M; Yasuda M; Ishizaki M; Kitagawa N; Ikejiri K; Inohara R; Lee BJ; Saino S; Sakado J; Matuzaka H; Numata K; Mandai M; Miyake K; Nakamura K Atherosclerosis; 1980 Nov; 37(3):333-42. PubMed ID: 7458980 [TBL] [Abstract][Full Text] [Related]
16. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias. Canzler H; Bojanovski D Artery; 1980; 8(2):171-8. PubMed ID: 7458684 [TBL] [Abstract][Full Text] [Related]
17. Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia. Hunninghake DB; Probstfield JL; Crow LO; Isaacson SO Metabolism; 1981 Jun; 30(6):605-9. PubMed ID: 7231197 [TBL] [Abstract][Full Text] [Related]
19. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475 [TBL] [Abstract][Full Text] [Related]
20. Lipoproteins and cholesterol esterification rate in men and women with hypercholesterolaemia of type IIa. Moberg B; Wallentin L Scand J Clin Lab Invest; 1981 Nov; 41(7):655-61. PubMed ID: 7339867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]